Acrivon Therapeutics, Inc. (ACRV)
NASDAQ: ACRV · Real-Time Price · USD
1.420
+0.010 (0.71%)
At close: May 5, 2025, 4:00 PM
1.410
-0.010 (-0.70%)
Pre-market: May 6, 2025, 4:49 AM EDT
Acrivon Therapeutics Stock Forecast
ACRV's stock price has decreased by -85.19% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Acrivon Therapeutics stock have an average target of 19.75, with a low estimate of 16 and a high estimate of 27. The average target predicts an increase of 1,290.85% from the current stock price of 1.42.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 28, 2025.
Analyst Ratings
The average analyst rating for Acrivon Therapeutics stock from 5 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 3 | 4 | 4 | 4 | 4 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 5 | 6 | 6 | 6 | 6 | 5 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $19 | Strong Buy | Reiterates | $19 | +1,238.03% | Mar 28, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Mar 26, 2025 |
| Citizens Capital Markets | Citizens Capital Markets | Buy Reiterates $17 | Buy | Reiterates | $17 | +1,097.18% | Mar 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $22 → $19 | Strong Buy | Maintains | $22 → $19 | +1,238.03% | Mar 26, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Jan 31, 2025 |
Financial Forecast
Revenue This Year
n/a
from 113.90M
Revenue Next Year
n/a
EPS This Year
-2.74
from -2.38
EPS Next Year
-2.75
from -2.74
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.2M | 11.0M | 45.1M | ||
| Avg | 169,024 | 1.8M | 9.3M | ||
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -98.9% | 6,422.7% | 2,427.6% | ||
| Avg | -99.9% | 956.1% | 420.7% | ||
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.35 | -2.18 | -1.88 | ||
| Avg | -2.74 | -2.75 | -2.57 | ||
| Low | -3.63 | -4.35 | -3.97 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.